T1	Participants 89 145	reatment-experienced hepatitis C virus-infected patients
T2	Participants 171 203	y 2 million Japanese individuals
T3	Participants 326 383	Patients in whom interferon (IFN)/ribavirin (RBV) therapy
T4	Participants 701 816	pegylated IFN/RBV treatment-experienced Japanese patients with hepatitis C virus subtype 1b or genotype 2 infection
T5	Participants 818 889	Patients without cirrhosis (aged 18-75 years) with subtype 1b infection
T6	Participants 1264 1288	One hundred ten patients
T7	Participants 1979 2047	Japanese patients with hepatitis C virus genotype 1b or 2a infection
T8	Participants 1782 1866	difficult-to-treat population of patients in whom prior pegylated IFN/RBV had failed
